Johnson & Johnson $JNJ Shares Sold by Intact Investment Management Inc.

Intact Investment Management Inc. reduced its holdings in Johnson & Johnson (NYSE:JNJ) by 18.2% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 71,389 shares of the company’s stock after selling 15,900 shares during the quarter. Intact Investment Management Inc.’s holdings in Johnson & Johnson were worth $10,905,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also modified their holdings of the company. GFG Capital LLC purchased a new stake in shares of Johnson & Johnson during the 2nd quarter valued at $35,000. Stone House Investment Management LLC purchased a new position in shares of Johnson & Johnson in the 1st quarter worth about $47,000. 1248 Management LLC acquired a new position in shares of Johnson & Johnson in the 1st quarter valued at about $48,000. Vermillion & White Wealth Management Group LLC increased its position in Johnson & Johnson by 66.4% during the 2nd quarter. Vermillion & White Wealth Management Group LLC now owns 376 shares of the company’s stock worth $57,000 after purchasing an additional 150 shares in the last quarter. Finally, Clal Insurance Enterprises Holdings Ltd raised its holdings in Johnson & Johnson by 390.0% in the first quarter. Clal Insurance Enterprises Holdings Ltd now owns 392 shares of the company’s stock valued at $65,000 after buying an additional 312 shares during the period. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Johnson & Johnson Price Performance

Shares of JNJ stock opened at $199.99 on Wednesday. The firm has a fifty day moving average of $194.74 and a two-hundred day moving average of $176.23. The firm has a market cap of $481.82 billion, a P/E ratio of 19.30, a P/E/G ratio of 2.25 and a beta of 0.36. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $207.81. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.07 and a quick ratio of 0.80.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. The business had revenue of $24.02 billion during the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%. As a group, research analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Tuesday, December 9th. Stockholders of record on Tuesday, November 25th were given a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.6%. The ex-dividend date was Tuesday, November 25th. Johnson & Johnson’s dividend payout ratio is presently 50.19%.

Analysts Set New Price Targets

JNJ has been the topic of a number of research reports. Royal Bank Of Canada reissued an “outperform” rating and issued a $209.00 target price on shares of Johnson & Johnson in a research note on Friday, October 10th. Bank of America raised their target price on Johnson & Johnson from $198.00 to $204.00 and gave the company a “neutral” rating in a report on Wednesday, October 15th. Scotiabank assumed coverage on Johnson & Johnson in a report on Thursday, November 13th. They issued a “sector outperform” rating and a $230.00 price target for the company. Wall Street Zen raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a research report on Saturday, September 13th. Finally, Loop Capital set a $190.00 target price on shares of Johnson & Johnson in a research note on Wednesday, October 22nd. Four investment analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and nine have given a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $203.15.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.